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Abstract
Improvements in technology and resources are helping to advance our understanding of cancer-initiating events as
well as factors involved with tumor progression, adaptation, and evasion of therapy. Tumors are well known to contain
diverse cell populations and intratumor heterogeneity affords neoplasms with a diverse set of biologic characteristics
that can be used to evolve and adapt. Intratumor heterogeneity has emerged as amajor hindrance to improving cancer
patient care. Polygenic cancer drug resistance necessitates reconsidering drug designs to include polypharmacology
in pursuit of novel combinatorial agents having multitarget activity to overcome the diverse and compensatory signal-
ing pathways in which cancer cells use to survive and evade therapy. Advances will require integration of different
biomarkers such as genomics and imaging to provide for more adequate elucidation of the spatially varying location,
type, and extent of diverse intratumor signaling molecules to provide for a rationale-based personalized cancer
medicine strategy.
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Introduction
In Sun Tzu’s book The Art of War, method and discipline are part of
the five constant factors governing one’s deliberations, which are
considered necessary to achieve success. In other words, proper assess-
ment of the strengths and weaknesses of your capabilities and those
of your opponent are crucial before engagement. For many centuries,
surgery was the only treatment option available for cancer patients.
Advancements in anesthesia, antiseptic practices, blood transfusions,
and antibiotics were landmark achievements providing for the field of
“surgical oncology” to develop. However, during this time the obser-
vation of cancer cell spread or metastasis necessitated additional devel-
opments including radiation therapy and chemotherapy. Initially, the
use of drugs involved cytotoxic chemotherapy for killing rapidly pro-
liferating cancer cells, which evolved to combination therapy using
drugs with different molecular mechanisms and toxicity profiles. It
has long been rationalized that the ability to eliminate a tumor required
identification of a druggable target presented by the tumor, which
could be exploited as a differentiable vulnerability (either by presence
or amount) apart from the host organism.
Attack by a Stratagem
The exquisite scientific progress achieved over the past few decades have
had a major impact in improving our understanding of tumor treat-
ment sensitivity and response to therapeutic interventions. In the cur-
rent post-genomic era, a clearer picture is emerging revealing an ever
increasing complex array of interconnected adaptable signaling path-
ways on which defined pathogenic driver mutations emerge and on
which tumor cells become addicted to for survival. This understanding
led to the establishment of a new generation of cancer drugs termed
molecularly targeted cancer therapies developed to block the growth
and spread of cancer through interfering with specific signaling mole-
cules involved in tumor growth and progression. Molecularly targeted
agents offered the ability to potentially treat genetically defined sub-
groups of patients by focusing on cellular and molecular alterations
specific to their individual cancer. Major clinical advances were antic-
ipated to be achieved through the development and use of targeted
agents based on the belief that targeted cancer therapies would be
more effective than traditional chemotherapy and radiotherapy. It
was also hoped that targeted cancer agents would provide additional
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benefits because while being less harmful to normal cells, systemic
side effects would be if not ameliorated altogether, at least mini-
mized, thus improving a patient’s overall quality of life. Further-
more, individualization of cancer patient care was now seen as
possible, as confirmation of the presence of a particular target within
a tumor could be achieved in a relatively straightforward manner
through molecular genomic analysis of an individual patient’s tumor
using a biopsy sample obtained from a patient’s tumor. By matching
the drug to the tumor target, major clinical successes seemed to be well
within reach.
Variation in Tactics
Experience has now showed that targeted therapies have limitations
that include potential for tumor cells to develop resistance. For ex-
ample, some patients have developed resistance to imatinib (Gleevec)
through a mutation in the BCR-ABL gene that alters the shape of the
protein so that its affinity for drug binding is reduced, decreasing treat-
ment efficacy. In fact, a wide variety of tumor cell adaptations in sig-
naling molecules may occur following exposure to targeted agents,
providing the cells with an opportunity to gain the upper hand through
acquired resistance, thus escaping elimination. Typically, alternative
targeted therapies that could possibly overcome the acquired resistance
are not available nor are the specific cellular adaptations that occurred
easily determined in real time. Owing to these issues in part, targeted
therapies are being used in combination with other targeted therapies
or with traditional chemotherapy and radiation therapy to provide for
a more aggressive treatment approach.
What was described thus far was an overall approach to cancer
treatment from the perspective of an individual tumor mass having
a single or major oncogenic driver that can be targeted following iden-
tification of the target through analysis of a biopsy sample. How-
ever, we now know that the composition of tumors can be comprised
of many different cell subpopulations, each which can harbor different
genotypic and phenotypic characteristics leading to a diversity of biol-
ogies. This knowledge can be very disconcerting, leaving one with the
feeling of “two steps forward and one step backwards” in the war on
cancer. The impact associated with the relatively recent understanding
of the presence of significant intratumor heterogeneity on tumor ther-
apy cannot be underestimated. Multiple cellular subpopulations with
different genetic and phenotypic characteristics along with their asso-
ciated tremendous three-dimensional spatial variation within a single
lesion portends the fact that a specific lesion does not have a single
target but rather multiple oncogenic targets that must be overcome
to achieve optimized therapeutic benefit [Yap TA (2012). Sci Transl
Med 4, 127].
Terrain
There are potentially a myriad of factors that can contribute to intra-
tumor heterogeneity. For example, heterogeneous cellular micro-
environments within a tumor mass can act to drive regional phenotypic
evolution and diversity with associated genetic mutations. For example,
spatially distinct regions within a tumor with limited blood flow would
have low oxygenation levels that could lead to tumor cells adapted to a
microenvironment of acidosis and hypoxia resulting in augmented sur-
vival pathways and enhanced resistance to chemoradiation. Moreover,
genetic instability within a tumor cell population provides opportu-
nities for the emergence of spatially varying cells expressing alternate
oncogenes and tumor suppressor genes further complicating the de-
velopment of an adequate treatment strategy for an individual tumor.
Recent findings have in fact revealed significant intratumor hetero-
geneity, and branched evolution was present in primary renal carcinomas
and associated metastatic sites using multiregion sequencing [Gerlinger M
(2012). N Engl J Med 366, 892]. In this study, multiregion genetic
analysis of four different tumors revealed that intratumor heterogeneity
was present in every tumor analyzed. Tumors were found to have spa-
tially separated heterogeneous somatic mutations, patterns of allelic
imbalance, and chromosomal imbalances that led to phenotypic intra-
tumor diversity and uniformity. It was also shown that a single tumor-
biopsy specimen only revealed a minority of genetic aberrations (including
mutations, allelic imbalance, and ploidy) that were actually present in
the tumor mass. Thus, characterization of intratumor heterogeneity
using next-generation sequencing necessitates our rethinking of how
best to approach the development of effective personalized medicine,
which, until now, has relied on single biopsy samples to delineate the
mutational landscape of a patient’s cancer. It is clear that genomic anal-
yses using single tumor-biopsy specimens underestimate the overall
mutational burden of tumors because the presence of significant intra-
tumor heterogeneity requires the issue of sampling bias to be addressed
to achieve improved outcome.
Intratumor heterogeneity of protein function may nurture tumor
adaptation through a Darwinian selection process leading to improper
selection of drugs resulting in an ineffective and thus disastrous treat-
ment outcome. Due to limitations in information obtainable from
single tumor-biopsy samples, the presence of intratumor heterogeneity
is anticipated to provide abridged information related to the true tumor
genomic landscape resulting in unending challenges to development of
personalized medicine for cancer patients. Due to the presence of in-
tratumor heterogeneity, intrinsic and acquired resistance to cytotoxic
chemotherapy, ionizing radiation, and molecularly targeted drugs is
an unavoidable consequence including the need to target multiple
oncogenic drivers of the tumor. One proposed solution is to use the
information related to polygenic drug resistance to develop a rationally
designed approach using combinatorial targeted therapy to address the
heterogeneity of targets disseminated throughout the tumor mass. One
of the key issues related to combination therapies is the potential for
severe and undesirable side effects. In an effort to minimize these tox-
icities, new approaches to drug development are incorporating si-
multaneous targeting moieties within a single structurally designed
molecule [Guerrant W (2012). J Med Chem 55, 1477]. Development
of novel multivalent ligands to modulate several cancer targets simul-
taneously may provide a useful approach for combating the inherent
intratumor heterogeneous diversity of protein function encountered
in clinical experience.
The Use of Spies
The concept of significant spatially varying somatic mutations along
with the need to delineate the major contributors of such within an
individual’s tumor necessitates the need for obtaining additional
multiregional information to optimize therapy and to predict treat-
ment outcome. Obtaining multiple biopsies may be problematic
especially in patients with multifocal metastatic disease and following
treatment wherein a tumor may adapt and thus gain resistance to the
intervention in real time. An alternate proposed strategy is to use state-
of-the-art clinical imaging modalities to complement the information
obtained from genetic analysis to further characterize tumor spatial
heterogeneity [Basu S (2011). Eur J Nucl Med Mol Imaging 38, 991].
Imaging can be used to reveal intratumor phenotypic heterogeneity
that likely reflects the underlying and spatially corresponding genetic
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diversity. For example, positron emission tomography, magnetic reso-
nance imaging (MRI), and computed tomography (CT) all provide
multislice high-resolution anatomic as well as functional images
that can be repeated over time before, during, and following treat-
ment intervention. These imaging modalities are well suited for inter-
rogating the three-dimensional landscape of tumors noninvasively and
over time. While traditional clinical assessment of tumor images is
conducted by a trained radiologist, the complexities and subtleties of
spatially varying signal intensities may be difficult to extract and inter-
pret by the naked eye. Traditionally, whole-tumor statistical averages
(histograms) of quantified imaging metrics have been used to character-
ize tumors before and following treatment. However, this type of
analysis relegates the spatial information to a whole-tumor average
measurement. More recently, emergence of a voxel-by-voxel–based
approach for quantifying changes over time spatially has been found
to provide more sensitivity for detecting changes over time during
therapy as well as retaining the spatial information within the anatomic
context of the tumor [Galban CJ (2011). Clin Cancer Res 17, 4760].
The voxel-based method has been applied across imaging modalities
and provides new opportunities to assess intratumor heterogeneity
[Laymon CM (2012). Magn Reson Imaging 30, 1278]. Additional
approaches for assessment of tumor heterogeneity using digital image
post-processing algorithms include texture analysis methods [Davnall F
(2012). Insights Imaging].
Imaging can provide significant and timely clinical patient manage-
ment support, as it can provide rapid and objective assessment of
tumor therapeutic response. However, response to therapeutic inter-
vention may be initially successful, but rapid emergence of spatially
varying resistance is likely and development of a noninvasive imaging
approach with the ability to detect this eventuality in a timely manner
would allow for rapid deployment of alternate interventions that
would be anticipated to optimize therapeutic outcome. Diffusion-
weighted MRI has been shown to provide a sensitive measure of
tumor response throughout the course of treatment. In addition,
diffusion-weighted MRI was reported to be sensitive enough to detect
real-time emergence of resistance in an animal tumor model [Lee
KC (2006). Cancer Res 66, 4692]. The overall ability of imaging
metrics to delineate spatially varying and treatment-associated changes
in tumor structure and function provides complementary informa-
tion to biopsy-derived molecular genetic information related to tumor
target presentation and will ultimately improve drug selection and
patient care.
Summary
As described above, genotypic and phenotypic diversity has a tremen-
dous impact on cancer growth and intervention. The journal Neoplasia
provides peer-reviewed diverse information related to basic cancer biol-
ogy, as it relates to clinical relevance and serves as a rapid conduit to
disseminate relevant and timely information to the international com-
munity. Exemplifying the significant diversity of articles published in
Neoplasia over the past 3 years, articles that cover areas of cancer re-
search including cell and tumor biology, imaging, genetics, experimen-
tal therapeutics, and clinical investigations are published (Table 1). The
readership of Neoplasia is provided with broad-based state-of-the-art
information comprising many key pieces of the overall oncology puzzle.
Furthermore, the immediate availability of Neoplasia articles to the
world-wide clinical cancer research community is a key feature of
Neoplasia, allowing authors’ research findings to be made available to
the largest possible readership ensuring that published articles will have
a significant impact. Finally, as the Editor in Chief and, along with the
Editorial Board, we have been pleased with the overall success that this
effort has in serving the cancer research community. We thank the
scientific groups who have entrusted the dissemination of their research
findings to our publication and we look forward to continued prog-
ress in knowledge, which will be used to improve cancer patient care
and outcome.
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